文献速递中毒与环境急症复苏、休克与脓毒症重症综合管理与镇静镇痛

氨氯地平暴露报告剂量与结局的关系:一项25年毒物中心回顾性审查

Relationship between reported dose and outcome in amlodipine exposures: a 25-year retrospective poison center review.
PubMed 文献 · Clin Toxicol (Phila) · 2025-09-04
一句话结论报告摄入氨氯地平≥400 mg者发生难治性休克和死亡风险高,作者认为可能受益于早期转至具备VA-ECMO能力的医疗中心。

该研究回顾俄勒冈毒物中心25年记录,纳入41例仅有氨氯地平暴露、报告了摄入剂量且使用血管活性/正性肌力药物的病例,分析报告剂量与同时使用血管活性/正性肌力输注最大数量、VA-ECMO使用及临床结局的关系。报告摄入≤250 mg(n=20)者很少需要超过两种血管活性/正性肌力输注,仅1例需要VA-ECMO,无死亡。报告摄入401-1,000 mg(n=14)者中12例(86%)接受四种或以上血管活性/正性肌力输注,6例(43%)接受VA-ECMO,4例(29%)死亡。作者结论认为报告摄入≥400 mg者难治性休克风险高,报告剂量可作为早期风险分层工具。

要点

  • 报告摄入氨氯地平≤250 mg(n=20)者很少需要超过两种血管活性/正性肌力输注,仅1例需VA-ECMO,无死亡。
  • 报告摄入401-1,000 mg(n=14)者中12例(86%)接受四种或以上血管活性/正性肌力输注,6例(43%)接受VA-ECMO,4例(29%)死亡。
  • 报告摄入701-1,000 mg的7例均接受四种或以上血管活性/正性肌力输注,4例(57%)接受VA-ECMO并存活。
  • 报告摄入701-1,000 mg未接受ECMO的3例中2例死亡,1例存活但需持续血液透析。
  • 作者认为报告摄入≥400 mg者难治性休克风险高,可能受益于早期转至具备VA-ECMO能力的医疗中心。

适用人群与场景

  • 俄勒冈毒物中心25年记录中仅氨氯地平暴露、报告了摄入剂量、未合并其他心血管活性物质共摄入且接受血管活性/正性肌力药物治疗的病例(n=41)。

红旗征与不能漏的情况

  • 氨氯地平摄入后达峰血浆浓度需数小时,中毒严重程度可能不会立即显现。
  • 氨氯地平毒性可导致对标准治疗无反应的深度血管麻痹性休克。

研究设计与关键结果

  • 回顾性毒物中心审查,纳入41例仅氨氯地平暴露、报告摄入剂量且使用血管活性/正性肌力药物的病例。
  • 报告摄入≤250 mg(n=20)者很少需要超过两种血管活性/正性肌力输注,仅1例需要VA-ECMO,无死亡。
  • 报告摄入401-1,000 mg(n=14)者中12例(86%)接受四种或以上血管活性/正性肌力输注,6例(43%)接受VA-ECMO,4例(29%)死亡。
  • 报告摄入701-1,000 mg的7例均接受四种或以上血管活性/正性肌力输注,4例(57%)接受VA-ECMO并存活;未接受ECMO的3例中2例死亡,1例存活但需持续血液透析。
  • 报告摄入剂量与血管加压药需求、VA-ECMO使用及死亡率相关。

证据类型、等级与局限

  • 证据类型:25年回顾性毒物中心审查。
  • 局限:样本量有限。

对床旁实践的改变

  • 作者认为报告氨氯地平摄入≥400 mg者难治性休克风险高,可能受益于早期转至具备VA-ECMO等高级干预能力的医疗中心。
  • 作者认为报告摄入剂量可作为临床医生有用的早期风险分层工具。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Amlodipine, a dihydropyridine calcium channel blocker, is a growing cause of poisoning fatalities in the United States. As it takes several hours following ingestion for amlodipine peak plasma concentrations to be reached, the severity of poisoning may not be immediately apparent to clinicians. This study aimed to stratify reported amlodipine exposure doses with the severity of clinical outcomes.

METHODS: We reviewed 25 years of Oregon Poison Center records to identify amlodipine exposures that included reported ingestion doses, did not involve other cardioactive co-ingestions and were treated with vasoactive/inotropic agents. We examined the relationship between the reported amlodipine dose, the maximum number of simultaneous vasoactive/inotropic infusions used during treatment, the use of veno-arterial extracorporeal membrane oxygenation, and clinical outcome.

RESULTS: Forty-one cases met the inclusion criteria. Reported ingestions of ≤250 mg (n = 20) rarely required more than two vasoactive/inotropic infusions; only one patient required veno-arterial extracorporeal membrane oxygenation, and no deaths occurred. For patients who reportedly ingested 401-1,000 mg (n = 14), 12 (86%) received four or more vasoactive/inotropic infusions, six (43%) received veno-arterial extracorporeal membrane oxygenation, and four (29%) died. Seven patients reportedly ingested 701-1,000 mg; all received four or more vasoactive/inotropic infusions, and four (57%) received veno-arterial extracorporeal membrane oxygenation and survived. Of the three who did not receive extracorporeal membrane oxygenation, two died, and one survived but required ongoing hemodialysis.

DISCUSSION: Amlodipine toxicity can result in profound vasoplegic shock refractory to standard therapy. Reported ingestion dose was associated with vasopressor requirements, utilization of veno-arterial extracorporeal membrane oxygenation, and mortality.

CONCLUSION: Although limited by sample size, these findings suggest that reported amlodipine ingestions of 400 mg or greater are at high risk for refractory shock and may benefit from early transfer to a medical center capable of advanced interventions such as veno-arterial extracorporeal membrane oxygenation. Reported ingestion dose may serve as a useful early risk stratification tool for clinicians.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Cowdery CP, Temple C. Relationship between reported dose and outcome in amlodipine exposures: a 25-year retrospective poison center review. Clin Toxicol (Phila). 2025. PMID: 40905687. doi:10.1080/15563650.2025.2539300

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。